Published Technical Disclosure Archive

Next-Generation Wound Healing Platform

Publication ID: 24-11857631_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Wound Healing Platform,” Published Technical Disclosure No. 24-11857631_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857631_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,631.

Summary of the Inventive Concept

A comprehensive wound healing platform leveraging advanced biomaterials, micro-needling, and AI-driven personalized medicine to revolutionize wound care.

Background and Problem Solved

The original patent's composition of a hydrogel and complex/coacervate of polycationic and polyanionic polymers with therapeutic proteins, while effective, has limitations in terms of controlled release, delivery, and patient-specific customization. The new inventive concept addresses these limitations by introducing a system for controlled release of multiple therapeutic proteins, micro-needling devices, and AI-driven personalized medicine.

Detailed Description of the Inventive Concept

The next-generation wound healing platform consists of a matrix of bio-responsive polymers that release proteins in response to changes in pH, temperature, or ionic strength. The composition is administered using a micro-needling device, which enables transdermal delivery and minimizes invasiveness. The system is integrated with a wearable patch and a database of patient-specific wound characteristics, allowing for computational modeling and prediction of optimal therapeutic protein release profiles. Machine learning algorithms and data from a plurality of sensors enable real-time adjustments to the composition and delivery regimen.

Novelty and Inventive Step

The new claims introduce the concept of bio-responsive polymers, micro-needling devices, and AI-driven personalized medicine, which are novel and non-obvious compared to the original patent. The combination of these elements enables a more efficient, effective, and patient-specific wound healing process.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different bio-responsive polymers, micro-needling devices with varying geometries, or alternative sensors and data sources for personalized medicine. Variations may also include the integration of additional therapeutic agents or the development of implantable devices for sustained release.

Potential Commercial Applications and Market

The next-generation wound healing platform has significant commercial potential in the wound care market, with potential applications in hospitals, clinics, and home care settings. The platform's ability to provide personalized medicine and improve patient outcomes may lead to increased adoption and market share.

CPC Classifications

SectionClassGroup
A A61 A61K47/36
A A61 A61K9/0019
A A61 A61K9/06
A A61 A61K35/16
A A61 A61K35/19
A A61 A61K38/177
A A61 A61K38/18
A A61 A61K38/1825
A A61 A61K38/195
A A61 A61K47/34
A A61 A61K47/42
A A61 A61L15/225
A A61 A61L15/40
A A61 A61L15/44
A A61 A61L27/18
A A61 A61L27/20
A A61 A61L27/225
A A61 A61L27/26
A A61 A61L27/3616
A A61 A61L27/52
A A61 A61L27/54
A A61 A61L27/56
A A61 A61L31/041
A A61 A61L31/042
A A61 A61L31/046
A A61 A61L31/145
A A61 A61L31/16
A A61 A61P9/10
A A61 A61L2300/25
A A61 A61L2300/252
A A61 A61L2300/414
A A61 A61L2300/418
A A61 A61L2400/04
A A61 A61L2430/20

Field of Art

Biomaterials, drug delivery systems, wound healing technologies, with expertise in polymer chemistry, protein engineering, and advanced medical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with advanced degrees, experience in polymer synthesis, protein delivery mechanisms, and familiarity with wound healing therapeutic strategies

Obviousness Rationale

A PHOSITA would recognize that the published technical disclosure represents a predictable extension of the source patent's core wound healing protein delivery technology by integrating known techniques in responsive polymers, micro-needling, and computational modeling. The fundamental mechanism of protein-polymer complex delivery remains consistent, with the novel contribution being the adaptive delivery platform and personalization approach. These variations represent incremental improvements using standard engineering design approaches within the wound healing technology domain.

Obvious Combinations & Variations

Source Patent Element
Hydrogel composition with polycationic and polyanionic polymers containing therapeutic proteins
PTD Variation
Bio-responsive polymer matrix that releases proteins in response to environmental triggers
Obviousness Reasoning
Responsive polymer design is a known technique for controlled drug delivery, and a PHOSITA would find it obvious to modify the source patent's static hydrogel with dynamic release mechanisms using standard polymer engineering principles
Source Patent Element
Complex of therapeutic proteins embedded in hydrogel
PTD Variation
Micro-needling device for transdermal delivery of protein complexes
Obviousness Reasoning
Micro-needling is a well-established minimally invasive drug delivery technique, and a PHOSITA would recognize its applicability to protein-based wound healing compositions as a predictable design variation
Source Patent Element
Specific therapeutic proteins like FGF-2 and SDF-1α
PTD Variation
AI-driven personalized protein release profile based on patient-specific wound characteristics
Obviousness Reasoning
Computational modeling of drug delivery is an emerging standard technique, and a PHOSITA would find it obvious to apply machine learning approaches to optimize protein therapy based on known clinical parameters
Source Patent Element
Polycationic polymer with specific peptide sequences
PTD Variation
Wearable patch with integrated sensor array for real-time composition monitoring
Obviousness Reasoning
Smart medical device integration is a predictable technological progression, and a PHOSITA would recognize the utility of adding sensor feedback to optimize protein delivery systems
Source Patent Element
Hydrogel-based protein delivery composition
PTD Variation
Alternative bio-responsive polymer matrices with varied geometries and release characteristics
Obviousness Reasoning
Material science offers multiple approaches to polymer design, and a PHOSITA would understand that exploring alternative polymer configurations represents a standard engineering design approach
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857631 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable extensions of known wound healing protein delivery technologies through standard engineering design choices and well-established techniques in responsive materials, micro-needling, and computational modeling.

Original Patent Information

Patent NumberUS 11,857,631
TitleProtection and delivery of multiple therapeutic proteins
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION